FinnGen study is funded by Business Finland and the pharmaceutical industry partners. The funding allocated for the first three years (FinnGen1: 2017-2020) is approximately 40 M €. The whole budget exceeds 80 M€.

The graph belows shows the FinnGen expenditure distribution for the first three years of the study. The data is based on March 2020 situation / budget forecast. Half of the funding has been used to cover costs related to biobank sample collection and handling. The next largest items of expenditure are data processing & analyses activities (mainly personnel costs) and genotyping with ThermoFisher's array. In addition, significant investments to IT and data security have been made.

Graph showing the expenditure distribution of FinnGen.

The total budget exceeds 80 M €. Approximately 20 M € comes from Business Finland and the rest from the international pharmaceutical industry partners: AbbVie, AstraZeneca, Biogen, Celgene/Bristol-Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.